Global Mosunetuzumab Market Strategic Research Report

Scope of the Report

The global Mosunetuzumab market size is predicted to grow from US$ 93.91 million in 2025 to US$ 233 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032.

In 2025, global Mosunetuzumab production reached approximately 3,200units.Mosunetuzumab is a fully human IgG1 subtype CD20/CD3 bispecific monoclonal antibody that mainly targets the CD20 antigen on the surface of B lymphocytes and the CD3 receptor on the surface of T lymphocytes. It bridges tumor B cells and cytotoxic T cells to activate T cell-mediated immune killing, thereby specifically eliminating malignant B cells. Administered via intravenous injection, this drug is mainly indicated for the treatment of B-cell non-Hodgkin lymphomas such as relapsed or refractory follicular lymphoma. As a tumor immunotherapeutic agent, it features high targeting specificity and distinct antitumor activity.

Mosunetuzumab, as the world’s first CD20/CD3 bispecific antibody approved for relapsed or refractory follicular lymphoma, has established a core position in the later-line treatment of indolent lymphomas by virtue of its innovative T-cell bridging mechanism, high remission rate and favorable safety profile. Its “off-the-shelf” nature significantly improves treatment accessibility and avoids the individualized preparation cycle required for CAR-T therapies. With the approval of the subcutaneous formulation, administration convenience has been greatly enhanced, further promoting the popularization of its clinical application. In the market, the drug has been included in authoritative clinical guidelines both at home and abroad, with its indications continuously expanding to front-line settings and combination regimens under active exploration. In the global competitive landscape, it forms differentiated complementation with similar bispecific antibodies, ADCs and CAR-T products, occupying a stable market share thanks to its structural advantages and long-term therapeutic benefits. As a key focus of global layout, the Chinese market is expected to witness continuous improvement in accessibility and remarkable growth potential with domestic approval and potential insurance coverage. Overall, mosunetuzumab is reshaping the treatment landscape of follicular lymphoma and is expected to move from later-line to front-line therapy in the future, becoming a key regimen contributing to functional cure.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Mosunetuzumab market?

What factors are driving Mosunetuzumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Mosunetuzumab market opportunities vary by end market size?

How does Mosunetuzumab break out by Type, by Application?

This report presents a comprehensive overview of the global Mosunetuzumab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 1 mg / vial
• 30 mg / vial

Segment by Route of Administration

• Intravenous Infusion
• Subcutaneous Injection

Segment by Combination Therapy

• Mosunetuzumab In Combination With Polatuzumab Vedotin 莫妥珠单抗联合用药的临床试验数据 莫妥珠单抗联合用药的作用机制 莫妥珠单抗联合用药的常见副作用有哪些？
• Mosunetuzumab In Combination With Lenalidomide

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• Relapsed or Refractory Follicular Lymphoma
• Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• Other Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mosunetuzumab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Other Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact